By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eisai Company, Ltd. 

4-6-10 Koishikawa, Bunkyo-ku

Tokyo    112-8088  Japan
Phone: 81-3-3817-3700 Fax: n/a


SEARCH JOBS


Key Statistics


Email: webmaster@eisai.co.jp
Ownership: Public

Web Site: Eisai Company, Ltd.
Employees: 7,043
Symbol: ESALY.PK
 









Company News
Eisai Company, Ltd. (ESALY.PK) Sues The FDA To Regain "Lost" Marketing Time For Its Drugs 8/18/2014 6:14:23 AM
Eisai Company, Ltd. (ESALY.PK) Submits First Marketing Authorization Application For Anticancer Agent Lenvatinib In Japan 7/18/2014 7:46:23 AM
Lexicon Pharmaceuticals, Inc. (LXRX) Brings In Ex-Eisai Company, Ltd. (ESALY.PK) Exec As New President And CEO 7/8/2014 6:22:48 AM
Sarepta Therapeutics (SRPT) Quietly Buys Eisai Company, Ltd. (ESALY.PK)'s Vacant R&D Lab In Cambridge For $25 Million 7/7/2014 6:41:06 AM
Boston Strategics Corporation Announces Licensing Deal With Eisai Company, Ltd. (ESALY.PK) 7/1/2014 11:17:42 AM
Eisai Company, Ltd. (ESALY.PK)'s R&D Subsidiary Kan Research Institute Commences Full-Scale Operation at New Facility 5/30/2014 9:47:09 AM
Eisai Company, Ltd. (ESALY.PK) Receives Positive Opinion From European Medicines Agency's CHMP On Expanding 5/30/2014 9:44:05 AM
Eisai Company, Ltd. (ESALY.PK) Enters Collaboration With Liverpool School Of Tropical Medicine And University of Liverpool To Discover Novel Anti-Wolbachia Targeted Anti-Filarial Drugs 3/20/2014 10:12:39 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) Buys Rights To Eisai Company, Ltd. (ESALY.PK) Alzheimer's Drugs, Amount Undisclosed 3/5/2014 6:32:22 AM
Eisai Company, Ltd. (ESALY.PK)'s Lenvatinib Phase 3 Trial Meets Primary Endpoint Of Progression Free Survival In Radioiodine-Refractory Differentiated Thyroid Cancer 2/3/2014 6:46:01 AM
12345678910...
//-->